Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
January 4, 2026
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig
January 3, 2026
Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan
January 2, 2026
Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing
January 2, 2026
Public Health 2025 Review: Prevention Under Pressure and Signals Too Loud to Ignore
January 1, 2026
Cardiovascular 2025 Review: From late rescue to earlier, smarter intervention
January 1, 2026
Rare Disease 2025 Review: From Orphan Innovation to a System-Level Stress Test
December 31, 2025
Immunology 2025 Review: From Mechanism Proliferation to Platform Discipline
December 30, 2025
Endocrinology 2025 Review: Outcomes, Access, and Earlier Intervention
December 30, 2025